...
glmd-img

Galmed Pharmaceuticals Ltd, Common Stock

GLMD

NAQ

$3.04

+$0.01

(0.33%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.02M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0.0435
Volume info-icon
This is the total number of shares traded during the most recent trading day.
10.93K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.80
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.56 L
$15.1 H
$3.04

About Galmed Pharmaceuticals Ltd, Common Stock

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGLMDSectorS&P500
1-Week Return0.66%-0.33%-1.49%
1-Month Return5.57%-4.57%-0.37%
3-Month Return-62.36%-9.96%3.89%
6-Month Return-18.68%-5.67%9.34%
1-Year Return-41.28%2.53%25.19%
3-Year Return-99.12%-1.43%24.7%
5-Year Return-99.71%34.73%85.39%
10-Year Return-99.72%102.14%187.19%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue35.00K39.00K42.00K35.00K31.00K[{"date":"2019-12-31","value":83.33,"profit":true},{"date":"2020-12-31","value":92.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.33,"profit":true},{"date":"2023-12-31","value":73.81,"profit":true}]
Gross Profit(35.00K)(39.00K)(42.00K)(35.00K)(31.00K)[{"date":"2019-12-31","value":-3500000,"profit":false},{"date":"2020-12-31","value":-3900000,"profit":false},{"date":"2021-12-31","value":-4200000,"profit":false},{"date":"2022-12-31","value":-3500000,"profit":false},{"date":"2023-12-31","value":-3100000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses22.38M30.21M32.88M17.65M(7.49M)[{"date":"2019-12-31","value":68.05,"profit":true},{"date":"2020-12-31","value":91.88,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":53.68,"profit":true},{"date":"2023-12-31","value":-22.79,"profit":false}]
Operating Income(22.38M)(30.21M)(32.88M)(17.65M)7.49M[{"date":"2019-12-31","value":-298.67,"profit":false},{"date":"2020-12-31","value":-403.23,"profit":false},{"date":"2021-12-31","value":-438.88,"profit":false},{"date":"2022-12-31","value":-235.6,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense3.83M2.60M933.00K60.00K(13.66M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.8,"profit":true},{"date":"2021-12-31","value":24.33,"profit":true},{"date":"2022-12-31","value":1.56,"profit":true},{"date":"2023-12-31","value":-356.17,"profit":false}]
Pre-Tax Income(20.46M)(28.77M)(32.47M)(17.87M)(6.91M)[{"date":"2019-12-31","value":-2046100000,"profit":false},{"date":"2020-12-31","value":-2877100000,"profit":false},{"date":"2021-12-31","value":-3246700000,"profit":false},{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false}]
Income Taxes(1.92M)(1.16M)(519.00K)705.00K(14.98M)[{"date":"2019-12-31","value":-272.34,"profit":false},{"date":"2020-12-31","value":-164.68,"profit":false},{"date":"2021-12-31","value":-73.62,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2125.39,"profit":false}]
Income After Taxes(18.54M)(27.61M)(31.95M)(18.57M)8.07M[{"date":"2019-12-31","value":-229.7,"profit":false},{"date":"2020-12-31","value":-342.05,"profit":false},{"date":"2021-12-31","value":-395.79,"profit":false},{"date":"2022-12-31","value":-230.07,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income From Continuous Operations(20.46M)(28.77M)(32.47M)(17.87M)(7.54M)[{"date":"2019-12-31","value":-2046100000,"profit":false},{"date":"2020-12-31","value":-2877100000,"profit":false},{"date":"2021-12-31","value":-3246700000,"profit":false},{"date":"2022-12-31","value":-1786600000,"profit":false},{"date":"2023-12-31","value":-753500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(18.54M)(27.61M)(31.95M)(18.57M)(6.91M)[{"date":"2019-12-31","value":-1854100000,"profit":false},{"date":"2020-12-31","value":-2761000000,"profit":false},{"date":"2021-12-31","value":-3194800000,"profit":false},{"date":"2022-12-31","value":-1857100000,"profit":false},{"date":"2023-12-31","value":-691200000,"profit":false}]
EPS (Diluted)(0.97)(1.35)(1.32)(0.76)(3.26)[{"date":"2019-12-31","value":-97,"profit":false},{"date":"2020-12-31","value":-135,"profit":false},{"date":"2021-12-31","value":-132,"profit":false},{"date":"2022-12-31","value":-76,"profit":false},{"date":"2023-12-31","value":-326,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GLMD
Cash Ratio 6.82
Current Ratio 7.03

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GLMD
ROA (LTM) -29.31%
ROE (LTM) -52.67%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GLMD
Debt Ratio Lower is generally better. Negative is bad. 0.12
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.88

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GLMD
Trailing PE 0.04
Forward PE NM
P/S (TTM) 0.00
P/B 0.27
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.32
PEG NM

FAQs

What is Galmed Pharmaceuticals Ltd share price today?

Galmed Pharmaceuticals Ltd (GLMD) share price today is $3.04

Can Indians buy Galmed Pharmaceuticals Ltd shares?

Yes, Indians can buy shares of Galmed Pharmaceuticals Ltd (GLMD) on Vested. To buy Galmed Pharmaceuticals Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GLMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Galmed Pharmaceuticals Ltd be purchased?

Yes, you can purchase fractional shares of Galmed Pharmaceuticals Ltd (GLMD) via the Vested app. You can start investing in Galmed Pharmaceuticals Ltd (GLMD) with a minimum investment of $1.

How to invest in Galmed Pharmaceuticals Ltd shares from India?

You can invest in shares of Galmed Pharmaceuticals Ltd (GLMD) via Vested in three simple steps:

  • Click on Sign Up or Invest in GLMD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Galmed Pharmaceuticals Ltd shares
What is Galmed Pharmaceuticals Ltd 52-week high and low stock price?

The 52-week high price of Galmed Pharmaceuticals Ltd (GLMD) is $15.1. The 52-week low price of Galmed Pharmaceuticals Ltd (GLMD) is $2.56.

What is Galmed Pharmaceuticals Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Galmed Pharmaceuticals Ltd (GLMD) is 0.0435

What is Galmed Pharmaceuticals Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Galmed Pharmaceuticals Ltd (GLMD) is 0.27

What is Galmed Pharmaceuticals Ltd dividend yield?

The dividend yield of Galmed Pharmaceuticals Ltd (GLMD) is 0.00%

What is the Market Cap of Galmed Pharmaceuticals Ltd?

The market capitalization of Galmed Pharmaceuticals Ltd (GLMD) is $5.02M

What is Galmed Pharmaceuticals Ltd’s stock symbol?

The stock symbol (or ticker) of Galmed Pharmaceuticals Ltd is GLMD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top